Keynote Speaker
Cathy S. Cutler, PhD
Dr. Cathy Cutler brings more than 20 years of experience in the development and evaluation of radiopharmaceuticals, utilizing bioinorganic and radioanalytical chemistry to develop and evaluate radiopharmaceuticals for both diagnosis and therapy.
Dr. Cutler is Director of the Medical Isotope Research Production and Development group (MIRP) at Brookhaven National Laboratory and directs the Target Processing Labs (TPL). She brings more than 20 years of experience in the development and evaluation of radiopharmaceuticals, utilizing bioinorganic and radioanalytical chemistry to develop and evaluate radiopharmaceuticals for both diagnosis and therapy. Recently, Cutler was elected vice president elect of the Society of Nuclear Medicine and Molecular Imaging where she will be president in two years.
The MIRP group at Brookhaven operates the LINAC Isotope Producer (BLIP) that supplies radioisotopes for commercial production as well as several research radioisotopes. BLIP is currently evaluating the accelerator production of Ac-225. Additionally, she directs the Radiopharmaceutical Research and Production Labs (RRPL) that processes targets from the BLIP.
Before Brookhaven, from 1998 through 2015, Cutler was a member of the University of Missouri Research Reactor Center Radiopharmaceuticals Group. While at Mizzou, she developed reactor processing methods for radioisotopes such as Lutetium-177 and developed targeting molecules such as nanoparticles for selective delivery.
The Molecular Imaging and Theranostics Center (MITC) is Mizzou’s lead resource for developing radiopharmaceutical-based diagnostic imaging and therapeutic agents. As the culmination of university-wide interdisciplinary collaboration, MTIC supports the needs of investigators and advances research at MU, throughout the UM System — and beyond.
For questions, contact the College of Arts & Science at muASevents@missouri.edu or 573-882-4421.
